Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

Revance Therapeutics logo

About Revance Therapeutics Stock (NASDAQ:RVNC)

Advanced Chart

Key Stats

Today's Range
$3.65
$3.65
50-Day Range
$3.65
$3.65
52-Week Range
$2.76
$6.65
Volume
N/A
Average Volume
3.70 million shs
Market Capitalization
$381.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.45
Consensus Rating
Hold

Company Overview

Revance Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

RVNC MarketRank™: 

Revance Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 537th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Revance Therapeutics has received no research coverage in the past 90 days.

  • Read more about Revance Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Revance Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for RVNC.
  • Dividend Yield

    Revance Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Revance Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for RVNC.
    • Insider Buying vs. Insider Selling

      In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.10% of the stock of Revance Therapeutics is held by insiders.

    • Percentage Held by Institutions

      97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Revance Therapeutics' insider trading history.
    Receive RVNC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    RVNC Stock News Headlines

    Crown Laboratories Now Operates Under the Name Revance
    Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
    Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
    See More Headlines

    RVNC Stock Analysis - Frequently Asked Questions

    Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The business's quarterly revenue was up 20.2% compared to the same quarter last year.
    Read the conference call transcript
    .

    Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Home Depot (HD).

    Company Calendar

    Last Earnings
    8/08/2024
    Today
    7/14/2025
    Next Earnings (Estimated)
    8/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:RVNC
    CIK
    1479290
    Employees
    500
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $20.00
    Low Price Target
    $3.00
    Potential Upside/Downside
    +131.5%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.13
    Research Coverage
    8 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.93)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$323.99 million
    Net Margins
    -74.67%
    Pretax Margin
    -122.07%
    Return on Equity
    N/A
    Return on Assets
    -37.22%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.12
    Quick Ratio
    3.05

    Sales & Book Value

    Annual Sales
    $234.04 million
    Price / Sales
    1.63
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($1.73) per share
    Price / Book
    -2.11

    Miscellaneous

    Outstanding Shares
    104,390,000
    Free Float
    99,066,000
    Market Cap
    $381.02 million
    Optionable
    Optionable
    Beta
    0.90

    Social Links

    7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

    Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

    Get This Free Report

    This page (NASDAQ:RVNC) was last updated on 7/14/2025 by MarketBeat.com Staff
    From Our Partners